Breaking News
November 14, 2018 - Researchers to develop sports-specific classification system for blind football
November 14, 2018 - Preschool children show awake responses to naptime nonsense words
November 14, 2018 - Survey shows negative effect of vulvovaginal atrophy symptoms on quality of life for women
November 14, 2018 - Study sheds light on mechanisms that prevent autoimmune attack
November 14, 2018 - Sleep quality found to be worse for women who undergo surgical menopause
November 14, 2018 - New study provides deeper insight into chromosome segregation during mitosis
November 14, 2018 - Appendix removal is linked to lower risk of Parkinson’s
November 14, 2018 - Lifting weights for less than an hour a week may reduce cardiovascular disease risk
November 14, 2018 - Pulmonary rehabilitation rarely received by hospitalized COPD patients despite health benefits
November 14, 2018 - New anti-HER2 drug shows promising anti-tumor activity in gullet, stomach and bowel cancers
November 14, 2018 - Regular head circumference assessment of preterm babies can help identify long-term IQ problems
November 14, 2018 - Brigham investigators examine opioid use among Massachusetts adolescents, prescription trends
November 14, 2018 - Study defines biomarker in response to treatment of castration-resistant prostate cancer
November 14, 2018 - Study identifies potential therapeutic strategy for patients with clear cell renal cancer
November 14, 2018 - Bausch Health Announces U.S. Launch of Bryhali (halobetasol propionate) Lotion, 0.01%, for Plaque Psoriasis In Adults
November 14, 2018 - Alpha Fetoprotein (AFP) Tumor Marker Test: MedlinePlus Lab Test Information
November 14, 2018 - Researchers evaluate controversial treatment for Parkinson’s disease psychosis
November 14, 2018 - AI could help veterinarians code their notes
November 14, 2018 - Pre-schoolers with autism thrive in mainstream classroom settings
November 14, 2018 - Individual and work-related factors may help promote hospital physician engagement, finds study
November 14, 2018 - Complementary and alternative medicine is widely used by general population in England
November 14, 2018 - Study reveals link between tobacco availability and smoking during pregnancy
November 14, 2018 - Purdue researchers develop translucent base for silicon patches to deliver exact doses of biomolecules
November 14, 2018 - New technology based on moths and magnets could help treat genetic diseases
November 14, 2018 - Concussion-Related Biomarkers Vary Based on Sex, Race
November 14, 2018 - One more year of high school may shape waistlines later in life
November 14, 2018 - Dissecting high drug costs – Scope
November 14, 2018 - Study shows novel strategy to reduce breast cancer bone metastasis
November 14, 2018 - Empowering the NHS through Industry Partnerships
November 14, 2018 - One size does not fit all in obesity treatment, study finds
November 14, 2018 - Seeking ways to prevent ‘secondary cataracts’
November 14, 2018 - Change Within the Eye May Be Early Warning for Macular Degeneration
November 14, 2018 - Study of 500,000 people clarifies the risks of obesity
November 14, 2018 - Ultrasound releases drug to alter activity in targeted brain areas in rats | News Center
November 14, 2018 - Umass Amherst researchers battle against youth suicide in rural Alaska Native communities
November 14, 2018 - Cancer stem cells depend on amino acid metabolism, and it’s proving to be their Achilles’ heel
November 14, 2018 - Epigenetic link found between prenatal exposure to maternal smoking and offspring’s cardio-metabolic health
November 14, 2018 - Meditation, music may change biomarkers of cellular aging and Alzheimer’s disease in older adults
November 14, 2018 - Multidisciplinaryresearch teams selected to study age-related brain disorders
November 14, 2018 - The Current issue of “The view from here” is concerned with Informatics
November 14, 2018 - Researchers identify tool to help transgender women have a more authentic voice
November 14, 2018 - Four faculty members appointed to endowed professorships | News Center
November 13, 2018 - Research finds strongest evidence yet that obesity causes depression
November 13, 2018 - Researchers compare stools of breastfed and formula-fed infants
November 13, 2018 - Entasis Therapeutics Announces Zoliflodacin Phase 2 Results Published in The New England Journal of Medicine
November 13, 2018 - Gene changes driving myopia reveal new focus for drug development
November 13, 2018 - $6 million grant to support study of preeclampsia, atherosclerosis links | News Center
November 13, 2018 - Beneficial gut microbes metabolize high-fiber diet to improve heart health in mouse model
November 13, 2018 - Excessive use of social media through visual postings linked to increase in narcissistic traits
November 13, 2018 - Study finds why obesity both fuels cancer growth and helps immunotherapy to kill tumors
November 13, 2018 - Women prefer and invest more in daughters, while men favor sons
November 13, 2018 - With hospitalization losing favor, judges order outpatient mental health treatment
November 13, 2018 - Transgenic rat model may provide new insights into cerebral amyloid angiopathy
November 13, 2018 - Study identifies factors tied to greater risk of advanced liver disease in cystic fibrosis patients
November 13, 2018 - Risk of blindness among premature babies with low levels of blood platelets
November 13, 2018 - A new strategy for combatting antibiotic-resistant infections
November 13, 2018 - Study aims to find which outreach method is more effective at improving cancer screening rates
November 13, 2018 - Insufficient sleep duration linked with unhealthy lifestyle profile among children
November 13, 2018 - IIASA researchers introduce new, simple measure for human wellbeing
November 13, 2018 - Magnetic nanosprings used as targeted drug delivery agents for anticancer therapy
November 13, 2018 - Scientists examine FCMs containing silver nanoparticles
November 13, 2018 - Failed DNA repair triggers chromosomal chaos
November 13, 2018 - Study shows new emerging role of osteopontin in HCV-related hepatocellular carcinoma
November 13, 2018 - Food insecurity during pregnancy linked to severity of neonatal abstinence syndrome
November 13, 2018 - Majority of Americans are concerned about health threat posed by antibiotic resistance
November 13, 2018 - Addition of Elotuzumab Ups PFS in Refractory Multiple Myeloma
November 13, 2018 - Study finds women with pregnancy-related nausea, vomiting use marijuana more
November 13, 2018 - Lethal heart rhythm more likely to be found in patients with common heart failure
November 13, 2018 - Study provides new clues to origin and development of multiple sclerosis
November 13, 2018 - Climate change could pose threat to male fertility
November 13, 2018 - Researchers discover how mitochondria deploy a powerful punch against disease-causing bacteria
November 13, 2018 - AHA: Traumatic Childhood Could Increase Heart Disease Risk in Adulthood
November 13, 2018 - Feeling the Burn? | NIH News in Health
November 13, 2018 - Women’s birth canals in Kenya, Korea, Kansas not the same: study
November 13, 2018 - Fecal microbiota transplantation effective against ICI-associated colitis
November 13, 2018 - New physical activity guidelines released that urge people to “move more”
November 13, 2018 - Angiotensin receptor blockers improve sodium excretion in blacks
November 13, 2018 - New project seeks to address alarming injury rate in youth footballers
November 13, 2018 - Fish oil or omega 3 fatty acid supplements can prevent heart attacks finds study
November 13, 2018 - The Human Heart-in-a-Jar That Could One Day Replace Animal Testing
Scientists receive $5.1 million grant to develop stem cell-based therapy for blinding retinal conditions

Scientists receive $5.1 million grant to develop stem cell-based therapy for blinding retinal conditions

image_pdfDownload PDFimage_print

Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and the Stein Eye Institute have been awarded a $5.1 million grant from the California Institute for Regenerative Medicine to advance the development of a novel therapy for blinding retinal conditions.

The award by the California Institute for Regenerative Medicine, or CIRM, will support the development of a treatment that will use patients’ own skin cells to generate autologous induced pluripotent stem cells to derive retinal pigment epithelium cells, which are lost in many blinding eye conditions. The team, led by Dr. Steven Schwartz, will use the grant to drive the promising therapy to the next critical step toward a clinical trial in humans, submitting an investigational new drug application to the Food and Drug Administration.

“We’re grateful to CIRM and the people of California for this grant, which will allow our team to translate our research into a treatment for major causes of untreatable blindness such as macular degeneration,” said Schwartz, Ahmanson professor of ophthalmology and chief of the retina division at the UCLA Stein Eye Institute. “This pivotal investment brings hope to countless patients and families suffering with blinding eye disease.”

Retinal diseases affecting the center of vision, also called maculopathies, are the leading cause of blindness in the developed world and affect more than 10 percent of the U.S. population over 65. The number of people affected by this untreatable group of disorders, such as age related and myopic macular degeneration, and Stargardt’s macular dystrophy, is expected to increase to nearly 20 million in the nation by 2020.

Although disorders in this group can have varied underlying causes, they are all linked to the deterioration of the layer of retinal pigment epithelium cells beneath the retina, which lines the inner surface of the back of the eye. These cells are critical to vision; they maintain function of light-sensitive cells called photoreceptors, or rods and cones. Without the retinal pigment epithelium cells, the rods and cones cannot survive. Ultimately, the deterioration of these cells leads to the loss of photoreceptors and eventually to blindness.

The induced pluripotent stem cells maintain the genetic code of the individual from whom they originated. The cells also bear none of the hallmarks of age and instead appear much like very young cells. In the research, these induced pluripotent stem cells will be differentiated into a large volume of the patient’s own retinal pigment epithelium cells — between 50,000 and 500,000 — which will then be surgically transplanted into their own retinas. Pre-clinical research suggests these new cells will integrate with the patients’ remaining retinal pigment epithelium cells, rescue related eye tissue and spur regeneration of the surrounding tissue. Thus, these transplants may preserve or restore vision.

Replacing retinal pigment epithelium cells lost to disease with the stem cell-based cells has already been tested in a first-of-its-kind clinical trial led by Schwartz. That trial showed that retinal pigment epithelium cell replacement strategies are safe and possibly effective in addressing retinal blindness. However, these earlier trials used cells created from human embryonic stem cells, which require that patients take drugs that suppress the immune system longer term so that their bodies do not reject the foreign cells. These immunosuppressive drugs carry substantial health risks, particularly for the elderly.

By creating retinal pigment epithelium cells from patient-derived induced pluripotent stem cells, the new method developed by Schwartz and his team should not pose a risk that the cell therapy will be rejected by the patient’s immune system, thus likely eliminating the need for immune suppression. Because many maculopathies are age-related, this key improvement may make Schwartz’s novel treatment more accessible to the individuals who need it most.

Another difference between Schwartz’s method and previously studied treatments is that the new retinal pigment epithelium cells will be delivered to patients suspended in liquid rather than on a scaffold. This makes it possible for the treatment to be administered in a minimally invasive transplant surgery, which reduces risks and provides faster recovery time.

These two advantages open up the possibility of administering the cell therapy earlier in the course of macular diseases, when some functional tissue remains. Early intervention could be critical to the success of treatments for maculopathies because when diseased retinal pigment epithelium cells are lost, neighboring and essential tissues such as photoreceptors are compromised or disappear completely.

“We hope this research will improve upon the methods studied in previous trials, which showed promise but came with drawbacks and risks,” Schwartz said. “The project holds the possibility of developing a treatment that will preserve vision in patients with an early diagnosis, restore vision in patients with end-stage loss of vision, and carry fewer risks.”

Schwartz is developing this treatment in collaboration with a multi-disciplinary team comprised of stem cell biologists, ophthalmologists, retinal biologists, immunologists, transplant surgeons, bioengineers and regulatory experts. This group includes co-investigators Dr. Donald Kohn, professor of microbiology, immunology and molecular genetics, pediatrics and molecular and medical pharmacology; William Lowry, professor of molecular, cell and developmental biology; Jerome Zack, professor and chair of microbiology, immunology and molecular genetics; David Williams, professor of ophthalmology and neurobiology; Saravanan Karumbayaram, adjunct professor of microbiology, immunology and molecular genetics; and Zoran Galic, an associate professor of medicine, all members of the UCLA Broad Stem Cell Research Center; as well as Xiaoyang Wang, assistant professor of medicine and health services research.

This research is supported by the California Institute for Regenerative Medicine-funded UCLA-UCI Alpha Stem Cell Clinic and the UCLA Broad Stem Cell Research Center. This includes previous support from the Esther B. O’Keeffe Foundation, the Jean Perkins Foundation and the UCLA department of ophthalmology, which has support from Research to Prevent Blindness Inc., Louis & Harold Price Foundation, Lavery Foundation, and the Smidt Family Foundation.

The potential cell-based treatment for blinding retinal conditions is used in pre-clinical tests only and has not been tested in humans or approved by the Food and Drug Administration as safe and effective for use in humans.

Source:

https://stemcell.ucla.edu/news/51-million-grant-will-fund-research-develop-stem-cell-based-therapy-blinding-eye-conditions

Tagged with:

About author

Related Articles